New study probes brain tumor metabolism with drug combo

NCT ID NCT05717153

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early phase trial at Mayo Clinic is studying how two drugs, DFMO and AMXT 1501, change the metabolism of brain tumors (gliomas) in 18 adult patients. The goal is to measure molecules in the tumor's fluid to understand how these drugs affect tumor growth and survival. Participants will have a biopsy or partial tumor removal, and the study focuses on learning about tumor biology, not on treating the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse astrocytoma glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact